Cabozantinib in hepatocellular cancer: from preclinical experiments to observational studies
نویسندگان
چکیده
Based on the results of registration studies, drug cabozantinib, mechanism action which is determined by inhibition tyrosine kinases a relatively wide range cellular receptors, registered in treatment hepatocellular cancer, kidney cancer and thyroid cancer. This literature review collects data action, preclinical experiments phases I–III studies. Emphasis placed tolerability efficacy population patients.
منابع مشابه
Preclinical studies of 166Ho-chitosan for treatment of hepatocellular carcinoma
Introduction: Recently, due to the special characteristics of 166Ho and chitosan, 166Ho-chitosan complex was developed for treatment of tumors such as hepatocellular carcinoma. This complex has been lately prepared with high radiochemical purity in our lab. The preclinical studies of the complex however should be performed to evaluate the tracer concentration in target and...
متن کاملpreclinical studies of 166ho-chitosan for treatment of hepatocellular carcinoma
introduction: recently, due to the special characteristics of 166ho and chitosan, 166ho-chitosan complex was developed for treatment of tumors such as hepatocellular carcinoma. this complex has been lately prepared with high radiochemical purity in our lab. the preclinical studies of the complex however should be performed to evaluate the tracer concentration in target and normal tissues before...
متن کاملCancer Therapy: Preclinical Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
Purpose: MET signaling has been suggested a potential role in hepatocellular carcinoma (HCC) and associated with prometastasis during antiangiogenesis therapy. We investigated the potential association between MET expression and therapeutic response to sorafenib in patients with HCC. Antitumor effects of cabozantinib, a dual inhibitor of MET and VEGFR2, were examined in cultured HCC cells as we...
متن کاملCancer Therapy: Preclinical Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
Purpose: ROS1 rearrangement leads to constitutive ROS1 activation with potent transforming activity. In an ongoing phase I trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib shows remarkable initial responses in patients with non–small cell lung cancer (NSCLC) harboring ROS1 fusions; however, cancers eventually develop crizotinib resistance due to acquired mutations such as G2032R in ROS...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ??????? ???????? ? ?????????
سال: 2022
ISSN: ['2686-9594', '2686-7435']
DOI: https://doi.org/10.17650/2686-9594-2022-12-4-41-51